Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Twelve-month outcomes of a bioabsorbable implant for in-office treatment of dynamic nasal valve collapse. The Laryngoscope Sidle, D. M., Stolovitzky, P. n., Ow, R. A., Silvers, S. n., Matheny, K. n., Bikhazi, N. n., Wani, M. n., Scurry, W. C., Most, S. P. 2019

Abstract

To examine 12-month outcomes for in-office treatment of dynamic nasal valve collapse (NVC) with a bioabsorbable implant.Prospective, multicenter, nonrandomized study.One hundred sixty-six patients with severe-to-extreme class of Nasal Obstruction Symptom Evaluation (NOSE) scores were enrolled at 16 U.S. clinics (November 2016-July 2017). Patients were treated with a bioabsorbable implant (Latera, Spirox Inc., Redwood City, CA) to support the lateral wall, with or without concurrent inferior turbinate reduction (ITR), in an office setting. NOSE scores and Visual Analog Scale (VAS) were measured at baseline and 1, 3, 6, and 12 months postoperatively. The Lateral Wall Insufficiency (LWI) score was determined by independent physicians observing the lateral wall motion video.One hundred five patients were treated with implant alone, whereas 61 had implant + ITR. Thirty-one patients reported 41 adverse events, all of which resolved with no clinical sequelae. Patients showed significant reduction in NOSE scores throughout 12 months postoperatively (77.4?±?13.4 baseline vs. 36.2?±?22.7 at 1 month postoperatively, 33.0?±?23.4 at 3 months, 32.1?±?24.6 at 6 months, and 30.3?±?24.3 at 12 months; P?

View details for DOI 10.1002/lary.28151

View details for PubMedID 31254279